{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-026644","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.637079+00:00","generated_at":"2026-05-15T13:52:46.261908+00:00","sec_items":["1.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Incannex terminates $108.4M ATM sales agreement; announces enhanced Phase 2 dose-optimisation study","bullets":["Mutually terminated Sales Agreement with Curvature Securities and A.G.P., effective March 11, 2026.","Raised aggregate gross proceeds of ~$108.4M under the agreement prior to termination.","Issued press release announcing enhanced Phase 2 dose-optimisation study (likely IHL-42X for OSA).","Corporate presentation confirms cash position of ~$70M as of December 2025.","Pipeline includes Phase 2/3 trials for OSA, GAD, and RA with positive data reported August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-026644","json":"https://secwatch.observer/filing/0001213900-26-026644.json","markdown":"https://secwatch.observer/filing/0001213900-26-026644.md","text":"https://secwatch.observer/filing/0001213900-26-026644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026026644/0001213900-26-026644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026026644/ea0278415-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:52:46.261908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0d32a574d8fbff3ceb3afd40e51acd67e7cf49e","claim":"Incannex Healthcare Inc. terminated Sales Agreement with Curvature Securities, LLC and A.G.P./Alliance Global Partners valued at Aggregate gross proceeds of approximately $108.4 million; termination at will with no penalty (effective 2026-03-11).","evidence_excerpt":"On March 11, 2026, the Company and the Sales Agents mutually agreed to terminate the Sales Agreement, effective immediately.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026026644/0001213900-26-026644-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Curvature Securities, LLC and A.G.P./Alliance Global Partners"},{"label":"Value","value":"Aggregate gross proceeds of approximately $108.4 million; termination at will with no penalty"},{"label":"Effective","value":"2026-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}